



BOX SEQUENCE
PATENT
0933-149P

TECH CENTER 1600/2900

NOV 15 2001

RECEIVED

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant: ZAVIALOV et al. Conf.: 7527
Appl. No.: 09/424,080 Group: 1644
Filed: February 14, 2000 Examiner: M. Jamroz
For: COMPOSITIONS FOR ENHANCING
IMMUNOSUPPRESSANTS' PHARMACEUTICAL ACTIVITIES

REPLY TO RESTRICTION REQUIREMENT

Assistant Commissioner for Patents
Washington, DC 20231

November 13, 2001
(Tuesday after Fed. Holiday)

Sir:

In reply to the Restriction Requirement dated October 12, 2001, the following remarks are respectfully submitted in connection with the above-identified application.

IN THE SPECIFICATION

Please replace the paragraph beginning at page 4, line 16 with the following paragraph.

Recently, the attention was brought to the long-neglected role of type I interferons (INF- α , β , ω , τ) in the modulation of immune response (Belardelli F. and Gresser I., 1996, Immunol. Today 17, pp. 369-372). The immunomodulating activity of IFN- α , β , ω , τ is very complex and includes:

15/C
JM
12/4/01